Valuation: Cogstate Limited

Market Cap 469M 324M 284M 262M 245M 460M 30.55B 3.15B 1.22B 15.1B 1.22B 1.19B 52.36B P/E 2026 *
27.9x
P/E 2027 * 22.4x
Enterprise Value 411M 284M 249M 229M 215M 402M 26.75B 2.75B 1.07B 13.22B 1.06B 1.04B 45.84B EV / Sales 2026 *
4.88x
EV / Sales 2027 * 4.14x
Free-Float
54.16%
Yield 2026 *
1.12%
Yield 2027 * 1.49%

Last Transcript: Cogstate Limited

Current month+3.85%
1 month+1.61%
3 months+23.53%
6 months+18.12%
Current year+18.12%
1 week 1.89
Extreme 1.89
1.89
1 month 1.7
Extreme 1.704
1.89
Current year 1.26
Extreme 1.26
1.89
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 16/12/1999
Chief Executive Officer - 30/11/2005
Director of Finance/CFO - 31/01/2021
Director TitleAgeSince
Director/Board Member - 28/02/2011
Chairman 67 02/11/2009
Director/Board Member - 19/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 324M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.74%+9.14%+76.18%+119.90% 25.57B
Weighted average by Cap. +0.75%+8.71%+86.69%+140.75%

Financials

2026 *2027 *
Net sales 84.07M 58.05M 50.9M 46.91M 43.92M 82.36M 5.48B 564M 218M 2.71B 218M 213M 9.38B 96.14M 66.38M 58.21M 53.65M 50.23M 94.19M 6.26B 645M 250M 3.09B 249M 244M 10.73B
Net income 16.57M 11.44M 10.03M 9.24M 8.65M 16.23M 1.08B 111M 42.99M 533M 42.95M 42.01M 1.85B 20.73M 14.31M 12.55M 11.57M 10.83M 20.31M 1.35B 139M 53.8M 667M 53.74M 52.57M 2.31B
Net Debt -58.46M -40.37M -35.39M -32.63M -30.54M -57.28M -3.81B -392M -152M -1.88B -152M -148M -6.53B -70.91M -48.96M -42.93M -39.57M -37.05M -69.47M -4.62B -476M -184M -2.28B -184M -180M -7.92B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.760AUD
Average target price
3.175AUD
Spread / Average Target
+15.04%

Quarterly revenue - Rate of surprise